Wang Shuncong, Sun Tiantian, Sun Huanhuan, Li Xiaobo, Li Jie, Zheng Xiaobin, Mallampati Saradhi, Sun Hongliu, Zhou Xiuling, Zhou Cuiling, Zhang Hongyu, Cheng Zhibin, Ma Haiqing
1 Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, P.R. China.
2 Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China.
Tumour Biol. 2017 May;39(5):1010428317691677. doi: 10.1177/1010428317691677.
Non-small cell lung cancer is the most common malignancy in males; it constitutes the majority of lung cancer cases and requires massive medical resources. Despite improvements in managing non-small cell lung cancer, long-term survival remains very low. This study evaluated survival improvement in patients with non-small cell lung cancer in each decade between 1983 and 2012 to determine the impact of race, sex, age, and socioeconomic status on the survival rates in these patients. We extracted data on non-small cell lung cancer cases in each decade between 1983 and 2012 from the Surveillance, Epidemiology, and End Results registries. In total, 573,987 patients with non-small cell lung cancer were identified in 18 Surveillance, Epidemiology, and End Results registry regions during this period. The 12-month relative survival rates improved slightly across three decades, from 39.7% to 40.9% to 45.5%, with larger improvement in the last two decades. However, the 5-year-relative survival rates were very low, with 14.3%, 15.5%, and 18.4%, respectively, in three decades, indicating the urgency for novel comprehensive cancer care. In addition, our data demonstrated superiority in survival time among non-small cell lung cancer patients of lower socioeconomic status and White race. Although survival rates of non-small cell lung cancer patients have improved across the three decades, the 5-year-relative survival rates remain very poor. In addition, widening survival disparities among the race, the sex, and various socioeconomic status groups were confirmed. This study will help in predicting future tendencies of incidence and survival of non-small cell lung cancer, will contribute to better clinical trials by balancing survival disparities, and will eventually improve the clinical management of non-small cell lung cancer.
非小细胞肺癌是男性中最常见的恶性肿瘤;它占肺癌病例的大多数,需要大量医疗资源。尽管在非小细胞肺癌的治疗方面有所改善,但长期生存率仍然很低。本研究评估了1983年至2012年期间每十年非小细胞肺癌患者的生存改善情况,以确定种族、性别、年龄和社会经济地位对这些患者生存率的影响。我们从监测、流行病学和最终结果登记处提取了1983年至2012年期间每十年非小细胞肺癌病例的数据。在此期间,在18个监测、流行病学和最终结果登记处地区共识别出573,987例非小细胞肺癌患者。三个十年间12个月相对生存率略有提高,从39.7%提高到40.9%再到45.5%,最近二十年提高幅度更大。然而,5年相对生存率非常低,三个十年分别为14.3%、15.5%和18.4%,这表明新型综合癌症治疗的紧迫性。此外,我们的数据显示社会经济地位较低和白人种族的非小细胞肺癌患者在生存时间上具有优势。尽管非小细胞肺癌患者的生存率在三个十年间有所提高,但5年相对生存率仍然很差。此外,种族、性别和不同社会经济地位群体之间的生存差距在扩大也得到了证实。本研究将有助于预测非小细胞肺癌发病率和生存的未来趋势,通过平衡生存差距有助于更好地开展临床试验,并最终改善非小细胞肺癌的临床管理。